Eleven Biotherapeutics to Present at the 2017 BIO CEO & Investor Conference
February 07 2017 - 8:00AM
Business Wire
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage
clinical oncology company advancing a broad pipeline of novel
product candidates based on its Targeting Protein Therapeutics
(TPTs) platform, today announced that Stephen Hurly, President and
Chief Executive Officer, will present a company overview at the
2017 BIO CEO & Investor Conference in New York on Tuesday,
February 14, 2017 at 8:30 a.m. EST.
A live webcast can be accessed from the Investors & Media
section of Eleven's website, www.elevenbio.com. An archived replay
of the webcast will be available on the Company's website for 90
days after the conference.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage clinical oncology
company advancing a broad pipeline of novel product candidates
based upon the Company's targeted protein therapeutics (TPTs)
platform. The Company's TPTs incorporate a tumor-targeting antibody
fragment and a protein cytotoxic payload into a single protein
molecule in order to achieve focused tumor cell killing. The
Company believes its TPT approach offers significant advantages in
treating cancer over existing antibody drug conjugate technologies.
The Company believes its TPTs provide effective tumor targeting
with broader cancer cell-killing properties than are achievable
with small molecule payloads that require tumor cell proliferation
and face multi-drug resistance mechanisms. Additionally, the
Company believes that its TPT's cancer cell-killing properties
promote an anti-tumor immune response that will potentially combine
well with immune oncology drugs such as checkpoint inhibitors. For
more information please refer to the Company's website at
www.elevenbio.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170207005589/en/
Stern Investor RelationsHannah
Deresiewiczhannahd@sternir.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Sep 2023 to Sep 2024